174 related articles for article (PubMed ID: 27919177)
41. Comparison of 5-hydroxytryptophan signaling pathway characteristics in diarrhea-predominant irritable bowel syndrome and ulcerative colitis.
Yu FY; Huang SG; Zhang HY; Ye H; Chi HG; Zou Y; Lv RX; Zheng XB
World J Gastroenterol; 2016 Mar; 22(12):3451-9. PubMed ID: 27022227
[TBL] [Abstract][Full Text] [Related]
42. A case-control comparison of direct healthcare-provider medical costs of chronic idiopathic constipation and irritable bowel syndrome with constipation in a community-based cohort.
Herrick LM; Spalding WM; Saito YA; Moriarty J; Schleck C
J Med Econ; 2017 Mar; 20(3):273-279. PubMed ID: 27783533
[TBL] [Abstract][Full Text] [Related]
43. Incidence of post-infectious irritable bowel syndrome and functional intestinal disorders following a water-borne viral gastroenteritis outbreak.
Zanini B; Ricci C; Bandera F; Caselani F; Magni A; Laronga AM; Lanzini A;
Am J Gastroenterol; 2012 Jun; 107(6):891-9. PubMed ID: 22525306
[TBL] [Abstract][Full Text] [Related]
44. [A correlation study between diarrhea-predominant irritable bowel syndrome complicated functional dyspepsia patients of Gan-stagnation Pi-deficiency syndrome and gastrointestinal hormones].
Zhao L; Song W; Zhu P; Zhang Y; Bu P
Zhongguo Zhong Xi Yi Jie He Za Zhi; 2014 Oct; 34(10):1168-72. PubMed ID: 25509256
[TBL] [Abstract][Full Text] [Related]
45. Current and future pharmacological treatments for diarrhea-predominant irritable bowel syndrome.
Camilleri M
Expert Opin Pharmacother; 2013 Jun; 14(9):1151-60. PubMed ID: 23621801
[TBL] [Abstract][Full Text] [Related]
46. Management of irritable bowel syndrome with diarrhea: focus on eluxadoline.
Jones J; Lembo A; Heidelbaugh J; Kuritzky L; Lacy B
Curr Med Res Opin; 2021 Apr; 37(4):567-578. PubMed ID: 33566707
[TBL] [Abstract][Full Text] [Related]
47. AGA Clinical Practice Guideline on the Pharmacological Management of Irritable Bowel Syndrome With Diarrhea.
Lembo A; Sultan S; Chang L; Heidelbaugh JJ; Smalley W; Verne GN
Gastroenterology; 2022 Jul; 163(1):137-151. PubMed ID: 35738725
[TBL] [Abstract][Full Text] [Related]
48. Brain regions involved in moxibustion-induced analgesia in irritable bowel syndrome with diarrhea: a functional magnetic resonance imaging study.
Zhu Y; Wu Z; Ma X; Liu H; Bao C; Yang L; Cui Y; Zhou C; Wang X; Wang Y; Zhang Z; Zhang H; Jia H; Wu H
BMC Complement Altern Med; 2014 Dec; 14():500. PubMed ID: 25516481
[TBL] [Abstract][Full Text] [Related]
49. Relationship between use of selective serotonin reuptake inhibitors and irritable bowel syndrome: A population-based cohort study.
Lin WT; Liao YJ; Peng YC; Chang CH; Lin CH; Yeh HZ; Chang CS
World J Gastroenterol; 2017 May; 23(19):3513-3521. PubMed ID: 28596687
[TBL] [Abstract][Full Text] [Related]
50. Overlapping upper and lower gastrointestinal symptoms in irritable bowel syndrome patients with constipation or diarrhea.
Talley NJ; Dennis EH; Schettler-Duncan VA; Lacy BE; Olden KW; Crowell MD
Am J Gastroenterol; 2003 Nov; 98(11):2454-9. PubMed ID: 14638348
[TBL] [Abstract][Full Text] [Related]
51. Economic burden of irritable bowel syndrome in China.
Zhang F; Xiang W; Li CY; Li SC
World J Gastroenterol; 2016 Dec; 22(47):10450-10460. PubMed ID: 28058026
[TBL] [Abstract][Full Text] [Related]
52. The burden of illness of irritable bowel syndrome: current challenges and hope for the future.
Hulisz D
J Manag Care Pharm; 2004; 10(4):299-309. PubMed ID: 15298528
[TBL] [Abstract][Full Text] [Related]
53. The Effectiveness of Synbiotic Preparation Containing
Skrzydło-Radomańska B; Prozorow-Król B; Cichoż-Lach H; Majsiak E; Bierła JB; Kosikowski W; Szczerbiński M; Gantzel J; Cukrowska B
Nutrients; 2020 Jul; 12(7):. PubMed ID: 32635661
[TBL] [Abstract][Full Text] [Related]
54. Clinical and economic burden of obstructive hypertrophic cardiomyopathy in the United States.
Jain SS; Li SS; Xie J; Sutton MB; Fine JT; Edelberg JM; Gao W; Spertus JA; Cohen DJ
J Med Econ; 2021; 24(1):1115-1123. PubMed ID: 34493144
[TBL] [Abstract][Full Text] [Related]
55. Platelet serotonin transporter in patients with diarrhea-predominant irritable bowel syndrome both before and after treatment with alosetron.
Bellini M; Rappelli L; Blandizzi C; Costa F; Stasi C; Colucci R; Giannaccini G; Marazziti D; Betti L; Baroni S; Mumolo MG; Marchi S; Del Tacca M
Am J Gastroenterol; 2003 Dec; 98(12):2705-11. PubMed ID: 14687821
[TBL] [Abstract][Full Text] [Related]
56. Increased intestinal mucosal leptin levels in patients with diarrhea-predominant irritable bowel syndrome.
Liu DR; Xu XJ; Yao SK
World J Gastroenterol; 2018 Jan; 24(1):46-57. PubMed ID: 29358881
[TBL] [Abstract][Full Text] [Related]
57. A Narrative Review of Irritable Bowel Syndrome with Diarrhea: A Primer for Primary Care Providers.
Moshiree B; Heidelbaugh JJ; Sayuk GS
Adv Ther; 2022 Sep; 39(9):4003-4020. PubMed ID: 35869354
[TBL] [Abstract][Full Text] [Related]
58. Three-year follow-up of sacral nerve stimulation for patients with diarrhoea-predominant and mixed irritable bowel syndrome.
Fassov J; Lundby L; Laurberg S; Buntzen S; Krogh K
Colorectal Dis; 2017 Feb; 19(2):188-193. PubMed ID: 27328645
[TBL] [Abstract][Full Text] [Related]
59. Fall-related healthcare use and costs in neurogenic orthostatic hypotension with Parkinson's disease.
François C; Biaggioni I; Shibao C; Ogbonnaya A; Shih HC; Farrelly E; Ziemann A; Duhig A
J Med Econ; 2017 May; 20(5):525-532. PubMed ID: 28125950
[TBL] [Abstract][Full Text] [Related]
60. Clinical characteristics, treatment patterns, and economic burden in patients treated for neuroendocrine tumors in the United States: a retrospective cohort study.
Chuang CC; Bhurke S; Chen SY; Brulais S; Gabriel S
J Med Econ; 2015 Feb; 18(2):126-36. PubMed ID: 25325180
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
